Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmunity in systemic sclerosis: current concepts.

Francesco Boin1, Antony Rosen

  • 1Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Bldg. Center Tower, Suite 4100, Room 412, Baltimore, MD 21224, USA.

Current Rheumatology Reports
|May 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parallel course of calcinosis and cancer in a patient with anti-NXP2-positive dermatomyositis: A case report.

Modern rheumatology case reports·2026
Same author

A CD57+CD8+ T cell subset links T cell cytotoxicity to fibrotic lung disease in systemic sclerosis.

The Journal of clinical investigation·2026
Same author

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.

Annals of the rheumatic diseases·2026
Same author

Criteria for defining and dating onset of organ system involvement in systemic sclerosis.

Journal of scleroderma and related disorders·2025
Same author

Telomere Length of Peripheral Blood Leukocytes Predicts Disease Severity and Worse Survival in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
Same journal

Management of IgG4-Related Disease.

Current rheumatology reports·2026
See all related articles

Systemic sclerosis (SSc) involves fibrosis and vascular damage driven by autoimmunity. New autoantibodies and immune cell pathways are implicated, offering potential therapeutic targets for SSc.

Area of Science:

  • Immunology
  • Rheumatology
  • Pathology

Background:

  • Systemic sclerosis (SSc) presents with fibrosis, microangiopathy, and immune issues.
  • The precise role of autoimmunity in SSc pathogenesis is unclear.
  • While autoantibodies are linked to SSc manifestations, their direct pathogenic role is unproven.

Purpose of the Study:

  • To explore the role of novel autoantibodies and immune cell activation in SSc.
  • To investigate potential pathogenic mechanisms contributing to SSc-specific tissue and vascular damage.
  • To identify new therapeutic strategies targeting immune pathways in SSc.

Main Methods:

  • Recognition of novel autoantibodies targeting cellular/extracellular matrix antigens in SSc.
  • Analysis of T-cell activation, polarization, and immune effector cell activity.

Related Experiment Videos

  • Emerging technologies for measuring autoantigen-specific T-cell responses.

    • Main Results:

    • New autoantibodies may directly activate pathways causing SSc tissue and vascular damage.
    • Activated T cells contribute to a profibrotic environment.
    • Immune effector cells promote vascular damage via cytotoxicity or inflammation.

    Conclusions:

    • Autoimmunity, particularly novel autoantibodies and immune cell responses, plays a significant role in SSc.
    • Understanding these immune pathways is crucial for developing targeted therapies.
    • Advances in measuring immune responses may lead to novel disease-modifying strategies for SSc.